The adjustment in price target by Citigroup reflects a slight modification in valuation expectations for Axsome Therapeutics, likely due to updated analysis or market conditions. However, maintaining a Buy rating indicates a continued positive outlook on the company's prospects. The impact on the stock price may be neutral to slightly positive as the reduction in target price is minimal and the Buy rating is reaffirmed, suggesting confidence in the company's fundamentals.